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ABSTRACT
Gastrin releasing protein receptor specific bombesin (BBN) peptide-gold nanoconjugates were successfully synthesized using gold nanorods
and dithiolated peptide. The gold nanorod-bombesin (GNR-BBN) conjugates showed extraordinary in vitro stabilities against various
biomolecules including NaCl, cysteine, histidine, bovine serum albumin, human serum albumin, and dithiothreitol. Quantitative measurements
on the binding affinity (IC50) of GNR-BBN conjugates toward prostate and breast tumor cells were evaluated. The IC50 values establish that
GNR-BBN conjugates have strong affinity toward the gastrin releasing peptide receptors on both the tumors. Detailed cellular interaction
studies of GNR-BBN conjugates revealed that nanorods internalize via a receptor-mediated endocytosis pathway. The receptor specific
interactions of GNR-BBN conjugates provide realistic opportunities in the design and development of in vivo molecular imaging and therapy
agents for cancer.
Nanoparticles, due to their smaller sizes and associated
unique properties, provide unprecedented opportunities to
interrogate cellular and molecular processes with realistic
clinical applications.1-10 Specific types of nanoparticles are
being utilized as drug delivery vehicles, cellular biomarkers,
and cancer imaging and therapy agents.1-10 The multifaceted
applications of nanoparticles are the direct result of their
ability to deliver high payloads of drugs or biomarkers to
the desired sites within the body.1-10 Design and development
of tumor-specific nanoparticles could significantly amplify
the delivering capacity to a specific target of interest, without
affecting healthy cells.1-10 The target specificity in nano-
particles could be imparted by tagging with certain biovec-
tors, which navigate them to desired organ or site under in
vivo conditions. The most commonly used target vectors are
monoclonal antibodies and receptor-specific peptides.11-13
Although, both biomolecules have shown high targeting
abilities, the (in vivo) transport properties of monoclonal
antibodies and peptides differ drastically. Monoclonal anti-
bodies, due to their larger sizes, show poor in vivo mobility
resulting in time delayed and reduced uptake over the desired
target. Moreover, monoclonal antibodies are highly im-
munogenic, which lead to harmful side effects. In sharp
contrast, peptides being smaller in size bring various
advantages, namely, rapid blood clearance, ease in penetra-
tion of tumor vascular endothelium, increased diffusion rates
in tissue, and low immunogenicity. Receptors for peptides
are highly expressed on a variety of neoplastic and non-
neoplastic cells.14,15 Furthermore, receptor targeting peptides
have shown a high level of internalization within the tumor
cells via receptor-mediated endocytosis.16 The ability to
internalize probes within tumor cells is important for
delivering maximum payloads to tumor cells.14-16 These
attractive physical properties coupled with their smaller size
make peptides ideal candidates for developing new target-
specific nanoparticles. Therefore, we have designed and
developed peptide conjugated nanoparticles that may
circumvent some of the currently encountered problems.
Nanoparticles of gold continue to play pivotal roles in the
design and development of tumor imaging and therapy
agents.1-13 In particular, gold nanorods (GNRs) have attracted
much interest because of their unique photophysical proper-
ties, which make them ideal candidates for both tumor
imaging and therapeutic applications.11,17-25 Recent studies
are focused on utilizing GNRs as contrast agents for
photoacoustic tomography. Indeed, Motamedi and co-work-
ers have shown that engineered gold nanorods, under in vivo
conditions, exhibit significant optoacoustic contrast and
increase the diagnostic power of optoacoustic imaging
modality.21 Gold nanorods attached with deltorphin, a ligand
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with high affinity toward delta opioid receptor, have shown
selective absorption toward human colon carcinoma cells,
establishing the fact they can serve as contrast agents for
molecular imaging.26 On the therapy front, El-Sayed and co-
workers have utilized the plasmon absorption of gold
nanorods, in photothermal therapy, as an effective tool
against cancer cells.3 Oyelere et al. demonstrated that peptide-
coated gold nanorods can be used as nuclear targeting agents
for potential in vivo imaging applications.27 These literature
examples suggest that gold nanorods possess the potential
to serve as theranostics, wherein a singular agent can serve
as both diagnostic and therapeutic. The theranostic capability
of gold nanorods could be realized only when GNRs are
selectively localized at tumor sites. The selective delivery
of GNRs to tumoral region can be achieved by attaching a
target-specific vector. In this context, our studies are focused
on utilizing bombesin peptide as a target vector for conjuga-
tion with gold nanorods. We hypothesized that bombesin
(BBN) peptide can act as a vehicle to deliver gold nanorods
specifically to tumor cells. The general structure of gold
nanorod-bombesin peptide (GNR-BBN) conjugate is shown
in Figure 1.
The 14 amino acid peptide bombesin isolated from the
skin of the amphibian Bombina and related gastrin-
releasing peptides (GRP) exhibit an enhanced response
in a variety of tumor tissues, e.g., small cell lung, prostate,
breast, and colon cancer.28-31 BBN functions as potent
autocrine or paracrine growth factors for cells.28-31 In the
past decade, a wealth of information was generated on BBN/
receptor expression and physiological information. BBN
shows high affinity towards GRP receptor subtype BB2. GRP
receptors are overexpressed in many cancers, including
prostate, breast, and small cell lung cancer.28-31 Analogues
of bombesin with modified structures exhibited a similar or
even higher affinity for these receptors.28-31 Synthetic
peptides can be readily generated through automated solid
phase techniques. For our studies, we have synthesized and
utilized truncated bombesin analogue (BBN) as a vehicle to
target GRP receptors (Figure 1).
The main objective of our investigation is to examine
whether the synthetic bombesin peptide conjugated gold
nanorods can preferentially locate GRP receptors, which are
overexpressed in prostate and breast tumor cells for subse-
quent applications as theranostic agents. As part of our
overall goal on developing target-specific gold nanoparticles
for treatment of cancers,32-34 we carried out a systematic
investigation on the design and development of targeted gold
nanorods by conjugating with GRP-receptor avid bombesin
peptide. Our studies, for the first time to our knowledge,
establish that GNR-BBN conjugates have very high binding
affinity toward GRP receptors in cancer cells and internalize
via receptor-mediated endocytosis pathway. The results
reported in this letter include (i) synthesis and characteriza-
tion of gold nanorod-bombesin (GNR-BBN) conjugates,
(ii) in vitro stability studies of GNR-BBN conjugates toward
various biomolecules, (iii) evaluation of binding affinity
(IC50) values of GNR-BBN conjugates toward GRP recep-
tors overexpressed in prostate and breast tumor cells, and
(iv) evaluation of internalization mechanism of GNR-BBN
conjugates in cells.
Production of GNR-Bombesin Bioconjugates. Syn-
thetic analogues of bombesin have been proven to show a
similar binding affinity as the nascent bombesin peptide with
GRP receptors.28-31 On the basis of our extensive previous
studies, we have selected the peptide sequence shown in
Scheme 1 for conjugation with gold nanorods. In the present
study, GNRs of aspect ratio 3.1, capped with surfactant
cetyltrimethylammonium bromide (CTAB), have been em-
ployed. These GNRs show a strong absorption band at 725
nm due to longitudinal oscillations of electrons. The con-
ventional method of surface conjugation of biomolecules to
GNRs involved replacement of capping CTAB ligands with
monodentate thiolated biomolecules to form Au-S bonds.
Although the conjugation is very effective, it suffers a major
drawback as the Au-S bond undergoes an irreversible
oxidation and consequent elimination under biological condi-
tions. Elimination of these surface bound ligands from
nanoparticles leads to instant destabilization of these con-
jugates to form macroaggregates. In order to circumvent this
problem, we have utilized a cyclic dithio moiety, thioctic
acid (TA), as a linker between GNR and bombesin peptide
(Figure 1 and Scheme 1). This dithio moiety chelates with
gold atoms on the surface of GNRs leading to a more stable
cyclic structure. Indeed, TA conjugated gold nanospheres
(AuNPs) have shown extraordinary stability when compared
with that of monothiol bound gold nanoconjugates.35-44 For
example, Abad et al. have used 3 nm TA-AuNPs as highly
stable scaffolds for conjugation with cobalt(II) complex for
subsequent interaction with histidine-tagged protein,35 and
TA-AuNPs have also been reported as a biological probe
by attaching with electroluminescent luminol.36 Mirkin and
Graham have independently established the high stability
attained by AuNPs upon conjugation with
TA-oligonucleotides.37,38 Recently, Li and co-workers have
demonstrated the high in vitro and in vivo stabilities of
AuNPs coated with TA-PEG than that of AuNPs conjugated
with monothiol-PEG.44 These literature examples suggest that
TA can serve as ideal ligands for covalent binding of AuNPs
with antibodies or peptides for in vivo imaging and therapy
applications.44 Another reason for the choice of disulfide as
Figure 1. General structure of GNR-BBN conjugates.
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a starting material is based on the fact that this moiety is
stable under peptidic reaction conditions. In sharp contrast,
free thiols on peptidic reaction conditions form disulfides to
yield mixtures. This complication poses additional problems
during the synthesis of thiols containing peptides. In this
study, we have synthesized dithioctic acid conjugate of
bombesin peptide using standard Fmoc methodology using
solid phase support. We chose commercially available
thioctic acid as a ligand to covalently link gold and bombesin
peptide. Thioctic acid contains two functional groups, a
disulfide and a carboxylic group. The carboxyl group of
thioctic acid was attached with N-terminal of bombesin
peptide via conventional solid-phase peptide synthesis to
yield thioctic-bombesin conjugate (SS-BBN, Figure 1). The
dithiobombesin (SS-BBN) was purified by standard HPLC
methods. The SS-BBN peptide is remarkably stable at 4 °C
and shows no detectable decomposition even after 1 year.
The disulfide group in SS-BBN was utilized to conjugate
with GNRs.
The GNR-bombesin conjugates were synthesized by
stirring CTAB-GNRs (1) with SS-BBN peptide (Scheme
1). In order to coat different amounts of SS-BBN over the
surface of GNRs, we varied the GNR-to-SS-BBN ratio (1:
SS-BBN ) 1:1, 1:2, and 1:3; 2a, 2b, and 2c, respectively).
Typical experimental procedure involves dissolution of 1 and
SS-BBN in water-methanol mixture and stirring for 20 h.
From the resulting mixture, GNR-BBN conjugates were
removed by centrifuging the solution at 8000g. The residue
was washed several times with water and methanol to remove
CTAB molecules and unreacted SS-BBN peptide. The
UV-visible spectra of GNR-BBN conjugates show a slight
change in the plasmon absorption band from that of 1 (Figure
2a). The examination of GNR-BBN conjugates under
transmission electron microscopy revealed distinct rod-
shaped structures with no sign of aggregation or change in
shape, with an average aspect ratio of 3.1; this size is
comparable to that of 1 (Figure 2b). We believe the
coexistence of both disulfide and ring structure in SS-BBN
provides synergistic advantages in rigid binding with gold
nanoparticles.
We examined the degree of bombesin coating in 2a, 2b,
and 2c by treating the aqueous solution of the conjugates
with 10% NaCl solution, followed by monitoring the plasmon
resonance band. If the coating of SS-BBN peptide over
GNRs is insufficient, then the surface gold atoms will be
exposed to ionic NaCl solution. This event triggers aggrega-
tion of the nanoparticles resulting in the broadening of
absorption band. Of the three conjugates, 2a and 2b show
broadening of the longitudinal plasmon absorption band after
mixing with 10% NaCl. On the other hand, the UV-visible
plasmon resonance band of 2c remains unaltered after
treatment with 10% NaCl. This observation unequivocally
demonstrates that in 2c the surface atoms are covered by
SS-BBN peptides. In order to ascertain the conjugation of
SS-BBN over GNR, we measured the zeta potential (-
potential) of GNR-CTAB and GNR-BBN (2c) conjugates.
The -potential of CTAB-coated gold nanorods is +48.0 mV
because of the presence of cationic CTAB on the surface.
The -potential of 2c is -32.0 mV. The resulting negative
charge in GNR-BBN conjugate can be attributed to negative
surface charge in “naked” gold nanorods.
In Vitro Stability Studies of GNR-BBN Conjugate.
The in vitro stabilities of GNR-BBN conjugates were
evaluated by treating aqueous solutions of nanoconjugates
with various biologically relevant molecules for 12 h,
followed by monitoring the plasmon resonance band (Figure
3). The molecules that are commonly encountered under in
vivo conditions include NaCl, HSA, cysteine, histidine, and
biological buffer additives such as dithiothreitol (DTT).
These molecules possess the ability to dislodge thiolated
ligands from gold-thiol nanoconjugates. The removal of
thiolated ligands would lead to aggregation of gold nano-
Scheme 1. Synthesis of GNR-BBN Conjugates (2a-2c) Followed by Treatment with 10% NaCla
a Plasmon resonance bands of 2a and 2b show broadening after mixing with 10% NaCl, whereas the plasmon band of 2c remains unaltered.
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particles, resulting in broadening of the plasmon resonance
band. Therefore, this study may provide greater understand-
ing on the in vivo stability of the conjugates. The aqueous
solutions of 2c were mixed with 0.9% NaCl, 0.5% cysteine,
0.2 M histidine, 0.5% HSA, or 0.5% BSA solutions and
stirred for 12 h, and the UV-visible spectra of the resulting
solutions were recorded (Figure 3a). It is important to
recognize that the plasmon absorption bands of 2c did not
show any change in peak width or shape (Figure 3).
The examination of thiolated gold nanoconjugates in the
presence of DTT is emerging as a standard test in establishing
in vitro stability.37,38 For example, gold-monothiol conju-
gates upon treatment with DTT releases more than 70% of
the thiols from the gold surface, within 12 h of treatment.
The rate of release of bound ligands from the surface serves
as a direct measure on the stability of the conjugate under
biological conditions. In the case of gold-dithiol conjugates,
the release of dithiol ligand from the surface of gold is very
Figure 2. GNR-CTAB and GNR-BBN conjugates: (a) UV-vis spectra; (b) transmission electron microscopy images.
Figure 3. In vitro stability studies of GNR-BBN conjugate 2c in various biological media: (a) UV-visible spectra of 2c after 12 h of
treatment with 0.9% NaCl, cysteine, histidine, HSA, or BSA; (b) UV-visible spectra of 2c in various time points after treatment with DTT
at 40 °C.
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limited. This in vitro stability can be attributed to strongly
chelating cyclic dithiols.
In order to unambiguously establish the stability of
conjugate 2c, we have monitored the aggregation charac-
teristics for 12 h after treatment with 10 mM DTT at 40 °C.
Typically, GNR-BBN conjugate 2c was treated with 10 mM
DTT solution and heated at 40 °C for 12 h. Release of bound
thioctic acid-bombesin peptide from GNR-BBN is ex-
pected to shift the plasmon bands of gold nanorods. Monitor-
ing the plasmon band provides the opportunity to comment
on the in vitro stability of 2c. The UV-visible spectra of 2c
after treatment with DTT were monitored for a period of
12 h (Figure 3b). The plasmon bands remained unaltered
throughout the period suggesting extraordinary in vitro
stability of 2c.
These data clearly confirm that 2c is highly stable in
solutions of NaCl, cysteine, histidine, HSA, BSA, or DTT.
It is conceivable that the chelate formed from the disulfide
ring structure contained within the SS-BBN backbone with
gold atoms provides extraordinary in vitro stability. These
findings provide solid corroboration that bonds between the
dithio moiety and gold atoms in GNR-BBN conjugates are
highly stable under in vivo conditions for further use in
imaging applications.
In Vitro Competitive Cell Binding Affinity Assays of
GNR-BBN Conjugate. Recently, Chan and co-workers
have evaluated the quantitative uptake of herceptin-coated
gold nanoparticles in ErbB2 overexpressing human breast
cancer SK-BR-3 cells using fluorescent imaging.4 In the
present report, we performed detailed competitive cell
binding affinity assays to evaluate IC50 values of conjugates
2a-2c in prostate (PC-3) and breast (T-47D) cancer cells.
Both PC-3 and T-47D cells exhibit a large number of GRP
receptors on the surface of the cells. The IC50 values of
GNR-BBN conjugates were determined against the radioac-
tive bombesin analogue 125I-Tyr4 BBN, which serves as a
GRP receptor specific peptide. In order to evaluate the IC50
values, the radioactive 125I-Tyr4 BBN was co-incubated with
increasing concentrations of GNR-BBN conjugates in PC-3
and T-47D cells. After the incubation period, cells were
washed several times and cell bound radioactivity was
measured. The IC50 values were determined by plotting the
cell-bound radioactivity of 125I-Tyr4 BBN versus the con-
centrations of GNR-BBN conjugates (Figure 4). Table 1
summarizes the IC50 values of GNR-BBN conjugates
2a-2c. The IC50 values for the conjugates were reported in
micrograms, as the molecular weights of the conjugates
cannot be accurately determined. It is evident from the data
that the IC50 values or cell binding affinity of conjugates
depend on the degree of BBN peptide coating over gold
nanorods. For instance, conjugate 2c, which has a greater
number of bombesin peptides on the surface of GNR,
exhibits a lower IC50 value (or higher cell-binding affinity)
when compared with other conjugates. The IC50 values of
GNR-BBN conjugates are comparable for both PC-3 and
T-47D cells. This study confirms that GNR-BBN conjugates
show high affinity toward GRP receptors overexpressed in
prostate cancer (PC-3 cell line) and breast cancer (T-47D
cell line).
Interaction of GNR-BBN with PC-3 and T-47D
Cancer Cells. The cellular localizations of GNR-BBN
nanoconjugates in PC-3 and T-47D cells, which overexpress
GRP receptors, were evaluated using dark field optical
microscopy and transmission electron microscope image
analysis. It is widely accepted that the internalization of
nanoparticles strongly depends on their physical character-
istics including size, shape, and charge. Recently, DeSimone
and co-workers have demonstrated that nanoparticles with
either larger size or negative zeta potential exhibit no cellular
internalizations.45 In that study, authors concluded that
investigating the internalization of nanoparticles bearing
negative zeta potential and conjugated with receptor-
stimulating ligand would be interesting. In order to deliver
negatively charged DNA inside the cells, researchers have
utilized ammonium ions as vectors; the ammonium cation
interacts effectively with a negatively charged cell membrane,
Figure 4. IC50 values of 2c against 125I-BBN in GRP receptors expressing (a) prostate tumor PC-3 cells and (b) breast tumor T-47D cells.
Table 1. Quantitative Measure of Binding Affinity (IC50)
of GNR-BBN Conjugates toward GRP Receptors
IC-50 value (µg/mL)
conjugate
PC-3
(prostate tumor cells)
T-47D
(breast tumor cells)
2a 11.89 7.57
2b 4.91 3.52
2c 2.62 2.12
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triggering charge-mediated endocytosis. It is important to
note here that GNR-BBN conjugate 2c has a negative
-potential of -32.0 mV. As a negative zeta potential
candidate, 2c is expected to have very minimal or no
interaction with negatively charged cell surface. In addition,
2c does not have any positively charged ions on the surface,
thus possesses no ability to trigger charge-mediated endocy-
tosis. These results indirectly suggest that internalization of
2c would be possible only by means of specific internaliza-
tion events. This behavior is also expected because the
bombesin sequence chosen in the present study has agonist
properties, which means they have specific receptor (in this
case, GRP receptor) triggering characteristics to internalize
within the cells. Our investigations focused on two important
aspects and they are as follows: (i) location of 2c within the
cellular matrices, and (ii) understanding the mechanism of
internalization of conjugate 2c in GRP receptors expressing
cancer cells.
As a first step, we recorded dark field light-scattering
images of T-47D cells after incubation with 2c (Figure 5).
The bright light scattering in the dark field image is due to
the presence of a unique longitudinal surface plasmon
oscillation which has a resonance frequency within the near-
IR region of the optical spectrum. The images confirm that
nanoparticles, as expected, have not entered into the nucleus.
Our detailed investigations used transmission electron mi-
croscopy (TEM) images and are discussed in the following
sections.
Receptor-Mediated Endocytosis. The mechanism of
either phagocytosis or receptor-mediated endocytosis is
considered the “holy grail” of internalization of nanoparticles
within cells. The widely accepted internalization mechanisms
for nanoparticles are via phagocytosis or receptor-mediated
endocytosis. In order to evaluate the internalization mech-
anism, we have carried out a detailed examination of TEM
images of cancer cells treated with 2c. TEM images, shown
in Figure 6, strongly suggest that the internalization occurs
via receptor-mediated endocytosis, and phagocytosis is not
observed. It is important to note that the cellular membrane
did not show the formation of phagocytic cups, which are
usually present in the cell wall if the phagocytosis has
occurred. In addition, the conjugates of 2c were not found
in endosomes but were present in cytosol (see Figure 6). It
is commonly observed that phagocytosed gold nanoparticles
form a dense mass of aggregated nanoparticles, secluded
from the rest of the cells in endosomal vesciles. Recently,
Brust and co-workers reported their results on the interaction
of citrate-stabilized nanoparticles and CALNN-coated nano-
particles with HeLa cells; they observed the formation of
densely packed aggregated nanoparticles in endosomes.46
Further, these studies have unequivocally demonstrated the
delivery of nanoparticles conjugated with cell penetrating
peptides selectively to cytosol without any uptake within the
endosomes.46 In sharp contrast, the PEG-ylated nanoparticles,
which are devoid of any targeting vector, did not show any
sign of internalization.46 Therefore, we can infer that nano-
particles coated with receptor specific peptides can be
endocytosed predominantly via non-phagocytosis pathway.
The generalized view is that nanoparticles that are susceptible
for interaction with serum proteins, such as citrate-stabilized
nanoparticles, tend to be prone for phagocytosis. On the other
hand, if the nanoparticles are stable toward serum proteins
(for example, PEG-ylated nanoparticles) which lack cell
targeting capabilities, they will not be internalized into the
cells. In the light of these findings, it is expected that
nanoconjugate 2c, which resists interaction with serum
protein, should not undergo phagocytosis. However, the
targeting vector bombesin in 2c is anticipated to stimulate
GRP receptors in the cellular surface, thus providing op-
portunity to penetrate into cells. In order to corroborate that
the internalization of GNR-BBN conjugates in PC-3 and
T-47D occurs via receptor-mediated endocytosis pathway,
our studies focused on understanding the interaction of
GNR-BBN conjugates with cells which lack GRP receptors.
For this experiment, we used NIH-3T3 cells, which do not
express GRP receptors.47 GNR-BBN conjugates 2c were
incubated with NIH-3T3 cells and monitored through TEM
images. As shown in Figure 7, significantly fewer GNRs
internalize in NIH-3T3 cells. Most importantly, the internal-
ized GNRs were present in endosomes and not in cytosol.
Our experimental results, as discussed above, have clearly
shown the uptake of bombesin-based nanoparticles in cytosol
when incubated with T-47D and PC-3 cells, both of which
are known to overexpress GRP receptors. These observations
corroborate that the mode of internalization of GNRs in NIH-
3T3 cells is predominantly via phagocytosis, whereas
Figure 5. (a) Dark-field image of breast tumor cells (T-47D) after
treatment with GNR-BBN conjugate 2c. (b) Fluorescence image
of nucleus of breast tumor cells. (c) Dark-field and fluorescence
overlap images indicating that GNRs are not localized in nuclei.
Figure 6. TEM images of cells after treatment with GNR-BBN
conjugate 2c: (a) PC-3 cells; (b) T-47D. GNR-BBN conjugates
are present in cytosol and show no formation of endosomes.
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internalization within PC-3 and T-47D proceeded via recep-
tor-mediated endocytosis pathway.
In summary, we have developed a novel strategy for the
synthesis of gold nanorod-bombesin (GNR-BBN) conju-
gates. The degree of coating of bombesin peptides over the
surface of GNRs can be tuned by adjusting the GNR-to-
SS-BBN ratio. Our detailed investigations confirm that
GNR-BBN conjugates show very high affinity toward
prostate and breast cancers, which overexpress GRP recep-
tors. The quantitative measure on the affinity of GNR-BBN
conjugates to various GRP-receptor positive tumors has been
evaluated. The internalization of GNR-BBN conjugates via
receptor-mediated endocytosis in GRP-receptor positive cells
was confirmed by TEM image analysis and dark field
microscopy analysis. Detailed investigations on the inter-
nalization mechanism of GNR-BBN have provided new
insights on the conjugates and confirm a receptor-mediated
endocytosis mechanism in GRP-receptor positive cells. The
selective cancer-targeting capabilities of GNR-BBN con-
jugates and the associated in vitro stabilities provide un-
precedented opportunities for the utilization of GNR-BBN
vectors in molecular imaging and therapy of cancer.
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